Evidence map›Paper›PMID 38182593›Full record

ArticleNPJ vaccines2024

Boosting with adjuvanted SCB-2019 elicits superior Fcγ-receptor engagement driven by IgG3 to SARS-CoV-2 spike.

Wonyeong Jung, Dansu Yuan, Benjamin Kellman, Isabela Garrido da Silva Gonzalez, Ralf Clemens, Eveline Pipolo Milan, Eduardo Sprinz, José Cerbino Neto, Igor Smolenov, Galit Alter and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 6 countries.

Wonyeong Jung *Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Dansu Yuan *Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Benjamin Kellman *Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0780-6096
Isabela Garrido da Silva GonzalezInstitute for Global Health, University of Siena, Siena, Italy.
Ralf ClemensInternational Vaccine Institute, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0003-4685-4207
Eveline Pipolo MilanCentro de Estudos e Pesquisa em Moléstias Infecciosas Ltda. (CEPCLIN), Natal, Brazil.ORCID http://orcid.org/0000-0002-5443-6315
Eduardo SprinzHospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.ORCID http://orcid.org/0000-0003-4343-8304
José Cerbino NetoD'Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0001-9254-917X
Igor SmolenovClover Biopharmaceuticals, Chengdu, China.
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7680-9215
Ryan P McNamaraRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. rpmcnamara@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-8866-3532
Sue Ann Costa ClemensOxford Vaccine Group, Department of Pediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.ORCID http://orcid.org/0000-0001-9576-0878
Ragon Institute of MGH, MIT and Harvard · USUniversity of Siena · ITClover Biopharmaceuticals (China) · CND’Or Institute for Research and Education · BRHospital de Clínicas de Porto Alegre · BRInternational Vaccine Institute · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the continued emergence of variants of concern, the global threat of COVID-19 persists, particularly in low- and middle-income countries with limited vaccine access. Protein-based vaccines, such as SCB-2019, can be produced on a large scale at a low cost while antigen design and adjuvant use can modulate efficacy and safety. While effective humoral immunity against SARS-CoV-2 variants has been shown to depend on both neutralization and Fc-mediated immunity, data on the effectiveness of protein-based vaccines with enhanced Fc-mediated immunity is limited. Here, we assess the humoral profile, including antibody isotypes, subclasses, and Fc receptor binding generated by a boosting with a recombinant trimer-tag protein vaccine SCB-2019. Individuals who were primed with 2 doses of the ChAdOx1 vaccine were equally divided into 4 groups and boosted with following formulations: Group 1: 9 μg SCB-2019 and Alhydrogel; Group 2: 9 μg SCB-2019, CpG 1018, and Alhydrogel; Group 3: 30 μg SCB-2019, CpG 1018, and Alhydrogel; Group 4: ChAdOx1. Group 3 showed enhanced antibody FcγR binding against wild-type and variants compared to Groups 1 and 2, showing a dose-dependent enhancement of immunity conferred by the SCB-2019 vaccine. Moreover, from day 15 after vaccination, Group 3 exhibited higher IgG3 and FcγR binding across variants of concerns, including Omicron and its subvariants, compared to the ChAdOx1-boosted individuals. Overall, this highlights the potential of SCB-2019 as a cost-efficient boosting regimen effective across variants of concerns.

Identifiers

PMID38182593
PMCPMC10770118
OpenAlexW4390618514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.